- The FDA is planning to allow Americans to get a different booster shot of a COVID-19 vaccine than the one initially taken, the New York Times reported.
- The move could potentially reduce the appeal of the Johnson & Johnson JNJ vaccine and provide flexibility to doctors and other vaccinators.
- The government would not recommend one shot over another, and it might note that using the same vaccine as a booster when possible is preferable, the NYT report said, citing people familiar with the agency's plans.
- The researchers presented the findings of a federally funded "mix and match" study.
- Related: NIH-Backed US Study Of Mixed COVID-19 Vaccines Regime To Conclude Soon: CNBC.
- The study found that recipients of Johnson & Johnson's single-dose shot who received a Moderna Inc MRNA booster saw their antibody levels rise 76-fold in 15 days, compared with a fourfold increase after the JNJ booster.
- The FDA is expected to authorize boosters of the Moderna and Johnson & Johnson vaccines by Wednesday.
- Related: Johnson & Johnson's COVID-19 Booster Dose Wins FDA Adcomm Backing.
- Price Action: JNJ shares traded 0.39% lower at $159.50, and MRNA shares are up 2.50% at $343.20 during the premarket session on the last check Tuesday.
- Photo by Johaehn from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in